Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Primary Effectiveness |
Primary Effectiveness is Primary Patency defined as patent blood flow through the study device, which requires either a Peak Systolic Velocity Ratio measurement = 2.5 or patent flow indicated by the Core Lab, and without repeat intervention measured at 12 months and assessed by Kaplan-Meier analysis. |
12 Months |
|
Primary |
Number of Subjects Free From Procedure and Device-Related Serious Adverse Events Within 30 Days of Index Procedure |
Primary Safety is defined as freedom from procedure and device-related serious adverse events within 30 days of index procedure |
30 Days |
|
Secondary |
Number of Subjects With Acute Procedural Success |
Acute Procedural Success is defined as successful delivery of the study device and complete coverage of the target lesion without a procedure or device-related Serious Adverse Event prior to hospital discharge. |
During hospitalization, approximately 1-2 days |
|
Secondary |
Primary Patency at 30 Days and 12, 24, and 36 Months |
Primary patency is defined as patent blood flow through the study device, which requires either a PSVR measurement = 2.5 or patent flow indicated by the Core Lab, without repeat intervention. |
30 days and 12, 24, and 36 months |
|
Secondary |
Primary Assisted Patency at 30 Days and 12, 24, and 36 Months |
Primary assisted patency is defined as blood flow through the study device regardless of repeat interventions to maintain patency prior to occlusion. |
30 days and 12, 24, and 36 months |
|
Secondary |
Secondary Patency at 30 Days and 12, 24, and 36 Months |
Secondary patency is defined as blood flow through the study device regardless of repeat interventions to restore patency after occlusion. |
30 days and 12, 24, and 36 months |
|
Secondary |
Freedom From Target Lesion Revascularization at 30 Days and 12, 24, and 36 Months |
Target Lesion Revascularization is defined as a repeat intervention within the study device and 5 mm proximal or distal to the edge of the study device to maintain or re-establish patency. |
30 days and 12, 24, and 36 months |
|
Secondary |
Freedom From Major Amputation at 30 Days and 12, 24, and 36 Months |
Major Amputation is defined as removal of the study limb above the metatarsals, resulting from a vascular event. |
30 days and 12, 24, and 36 months |
|
Secondary |
Change in Ankle Brachial Index at 30 Days |
The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. |
Pre-procedure and 30 Days |
|
Secondary |
Change in Ankle Brachial Index at 1 Year |
The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. |
Pre-procedure and 1 Year |
|
Secondary |
Change in Ankle Brachial Index at 2 Years |
The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. |
Pre-procedure and 2 Years |
|
Secondary |
Change in Ankle Brachial Index at 3 Years |
The Ankle Brachial Index (ABI) is the ankle systolic pressure in the study limb divided by the highest systolic pressure in either arm. ABI values <= 0.90 are considered abnormal, 0.91-0.99 borderline, 1.00-1.40 normal, and >1.40 noncompressible. The change in ABI was measured relative to that obtained pre-procedure. |
Pre-procedure and 3 Years |
|
Secondary |
Change in Rutherford Category at 30 Days |
The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. |
Pre-procedure and 30 Days |
|
Secondary |
Change in Rutherford Category at 1 Year |
The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. |
Pre-procedure and 1 Year |
|
Secondary |
Change in Rutherford Category at 2 Years |
The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. |
Pre-procedure and 2 Years |
|
Secondary |
Change in Rutherford Category at 3 Years |
The Rutherford Category is a lower limb ischemia classification with 7 categories ranging from least severe (category 0) to most severe (category 6): Category 0 - No claudication; Category 1 - Mild claudication; Category 2 - Moderate claudication; Category 3 - Severe claudication; Category 4 - Ischemic rest pain; Category 5 - Minor tissue loss, non-healing ulcer, focal gangrene with diffuse pedal ischemia; Category 6 - Major tissue loss, extending above transmetatarsal level, functional foot no longer salvageable. The change is Rutherford Category was measured relative to that obtained pre-procedure and a negative change corresponds to improved outcome. |
Pre-procedure and 3 Years |
|
Secondary |
Stent Fracture at 12, 24, and 36 Months |
Device stent fractures that are clearly distinguishable from previously implanted stents will be assessed by the study core lab through x-ray images. |
12, 24, and 36 months |
|